Eli Lilly’s blockbuster obesity drug Mounjaro emerged as India’s top-selling pharmaceutical product by value in October 2025, achieving sales of ₹1 billion (about $11.38 million), according to research firm Pharmarack. The surge in demand for anti-obesity medications—which aid in blood sugar regulation and slow digestion—has continued to accelerate in the world’s most populous country.
Mounjaro was launched in March, well ahead of rival Novo Nordisk’s Wegovy which entered the market in June. Since its debut, Mounjaro has generated a cumulative revenue of ₹3.33 billion through the end of October, reflecting robust demand and rapid adoption in India.
